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A novel membrane-soluble prodrug of the 5*-monophosphate derivative of 3TC containing a phenyl
group and the methyl ester of L-alanine linked to the phosphorus through a phosphoramidate bond with
the primary amino moiety (designated Cf 1109) was prepared. The 3TC prodrug proved less potent an
inhibitor of HIV-1 and HIV-2 replication in CEM cell cultures than 3TC, but lost only 20-fold antiviral
potency in 2*-deoxycytidine kinase-deficient CEM/dCK0 cells compared with a more than 2,000-fold
decrease of activity of 3TC. In contrast, 3TC and Cf 1109 proved equally highly effective in inhibiting
HBV release in supernatants of HBV-transfected Hep G2 2.2.15 cell cultures (50% effective concentration
 0.02 mM). Both compounds easily selected for highly resistant HIV-1 strains at a comparable speed of
breakthrough. The mutant viruses contained an 184-Ile and/or 184-Val amino acid change in their reverse
transcriptase. Our data are suggestive for a relatively poor delivery of 3TC-MP in the intact CEM cells but
a remarkably high delivery of 3TC and/or 3TC-MP in the intact Hep G2 2.2.15 cells. q 1996 Academic
Press, Inc.
The most recently approved 2*,3*-dideoxynucleoside (ddN) derivative for treatment of HIV
infections is 2*,3*-dideoxy-3*-thiacytidine (3TC, lamivudine) (Fig. 1). This drug is also subject
of clinical trials in human hepatitis B virus (HBV)-infected patients. In contrast with the other
approved (b-D) ddN derivatives has 3TC the b-L(0) isomeric conformation. 3TC needs to
be converted to its 5*-triphosphate derivative by cellular enzymes to be inhibitory to the reverse
transcriptase (RT) of HIV, and is endowed with low if any cytotoxicity (1-5). However, the
first activation (phosphorylation) step is catalysed by cytosolic 2*-deoxycytidine kinase (dCK)
which has a relatively poor affinity for 3TC (Ki/Km  50) resulting in a moderate efficiency
of conversion of 3TC to its 5*-monophosphate derivative (6). In addition, a potential drawback
of 3TC is the rapid emergence of drug-resistant HIV-1 strains (7-11). Indeed, mutant virus
strains that emerged in the presence of 3TC were shown to contain an amino acid change
from methionine (Met) to valine (Val) or isoleucine (Ile) at position 184 of the RT. Such virus
is highly resistant to the inhibitory effects of 3TC in cell culture (7-11), and is reported to
show low-level cross-resistance to 2*,3*-dideoxycytidine (ddC) (Fig. 1) and 2*,3*-dideoxyinos-
ine (ddI).
In an attempt to circumvent the first intracellular phosphorylation step of 3TC, we synthe-
sized the arylphosphoramidate derivative of 3TC containing a methylester of L-alanine linked
to the 5*-phosphate of 3TC-MP through its primary amino group (Fig. 1). The corresponding
2*,3*-didehydro-2*,3*-dideoxythymidine (d4T, stavudine) analogue (So324) was previously
shown to be able to deliver directly the 5*-monophosphate derivative of d4T into intact cells
and to efficiently bypass the first (thymidine kinase-directed) phosphorylation of d4T (12,13).
The antiviral potency and resistance profile of Cf 1109 is described compared to 3TC.
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FIG. 1. Structural formulae of 2*,3*-dideoxycytidine (ddC), 2*,3*-dideoxy-3*-thiacytidine (3TC, lamivudine) and
the arylphosphoramidate derivative of 3TC (Cf 1109).
MATERIALS AND METHODS
Viruses. HIV-1(IIIB) and HIV-2(ROD) were kindly provided by Prof. R.C. Gallo (National Cancer Institute, National
Institutes of Health, Bethesda, MD) and Dr. L. Montagnier (Pasteur Institute, Paris, France).
Cells. Wild-type CEM/0 cells were obtained from the American Tissue Cell Culture Collection (Rockville, MD),
the thymidine kinase-deficient (CEM/TK0) and 2*-deoxycytidine kinase-deficient (CEM/dCK0) cells were kindly
provided by Prof. S. Erikson (Uppsala, Sweden) and Prof. A. Karlsson (Stockholm, Sweden). Hep G2 2.2.15 hepatoblas-
toma cells were provided by Dr. G. Acs (Mount Sinai Medical Center, N.Y.).
Synthesis of 3TC 5*-[phenyl methoxyalaninyl]phosphate (Cf1109). Tertbutylmagnesium chloride (1.0 M in THF)
(1.0 ml, 1.1 eq) was added to a slurry of 3TC (0.21 g, 0.93 mmol) in pyridine (7 ml) and THF (50 ml) with
stirring, and the mixture was allowed to equilibrate for 0.5 h under a nitrogen atmosphere. Phenyl methoxyalaninyl
phosphorochloridate (1.0 M in THF) (2 ml, 2 mmol, 2 eq) was added with stirring, and the mixture was allowed to
stir for 2 h. The reaction mixture was diluted with dichloromethane (50 ml), quenched with saturated NH4Cl (100
ml) and extracted with dichloromethane (3 1 50 ml). The combined organic layers were washed with brine (30 ml),
dried over MgSO4 and the solvent removed in vacuo. The resulting residue was purified by flash column chromatogra-
phy (7% MeOH, 1% Et3N in CHCl3) to yield the product as a white solid (0.21 g, 48%) (M.Pt. 52-547C); dH (DMSO-
d6) 7.71 (1H, 2d, J7.5 Hz, H6), 7.30 (7H, m, OPhe, NH2), 6.25 (1H, t, J5.7 Hz, H1*), 6.14 (1H, m, Ala NH), 5.74
(1H, 2d, J7.5Hz, H5), 5.38 (1H, 2t, H4*), 4.29 (2H, m, H5*), 3.89 (1H, m, H4*), 3.60 (3H, s, OMe), 3.42 Ala CH),
3.06 (2H, m, H2*), 1.23 (3H, 2d, J6Hz, Ala Me); dp (DMSO-d6) 4.89, 4.52; dC (DMSO-d6) 176.563-176.343 (Ala
CO), 168.411 (C-4), 157.402 (C-2), 153.458-153.315 (Phe), 143.451 (C-6), 132.424 (Phe), 127.403 (Phe), 122.985-
122.856 (Phe), 97.078 (C-5), 89.706 (C-1*), 84.468-84.351 (C-4*), 69.692-69.444 (C-5*), 54.709 (OMe), 52.583-
52.400 (Ala CH), 38.404-38.325 (C-2*), 22.493-22.331 (Ala Me); nmax (cm01): 3341.2, 3197.3, 2988.0, 2932.3,
1740.8, 1651.8.
Antiviral activity of test compounds. CEM cells were suspended at 250,000 cells per ml of culture medium and
infected with approximately 100 CCID50 (1 CCID50 being the 50% cell culture infective dose) of HIV-1(IIIB) or
mutant HIV-1 strains selected for resistance against 3TC (11). Then, 100 ml of the infected cell suspensions was
added to 200-ml microtiter plate wells containing 100 ml of an appropriate dilution of the test compounds (i.e. 250,
100, 20, 4, 0.8, 0.16, 0.032, 0.006, 0.001 mg/ml). The inhibitory effect of the test compounds on HIV-1-induced
syncytium formation in CEM cells was examined on day 4 post infection as described previously (11). The 50%
effective concentration (EC50) was determined as the compound concentration required to inhibit syncytium formation
by 50%.
Peripheral blood lymphocytes (PBL) from a normal HIV-negative human volunteer were obtained by the Ficoll/
Hypaque technique, washed twice with phosphate-buffered saline (PBS) and cultured with phytohemagglutin (PHA,
2 mg/ml) for 3 days at 377C in a CO2-controlled incubator. PHA-stimulated PBL cells were washed twice with PBS
and then infected with a concentrated HIV-1 (HTLV-IIIB) stock in RPMI-1640 medium supplemented with 15% heat-
inactivated foetal calf serum, L-glutamine (2 mM), gentamicin (50 mg/ml), recombinant interleukin-2 (10 Units/ml)
and polybrene (2 mg/ml). After 60 min incubation at 377C, non-adsorbed virus was removed by successive washing
steps with fresh culture medium, and the HIV-1-infected PBL cells were then suspended at 5 1 105 cells/ml in RPMI-
1640 medium and cultured in the presence of varying concentrations (20, 4, 0.8, 0.16, 0.032 and 0.006 mM) of the
test compounds in 96-well culture plates (200 ml per well). HIV-1 p24 core antigen was quantified in the cell culture
supernatants at 7 days after infection by an antigen-capture assay using an ELISA technique.
For analysis of extracellular HBV DNA, Hep G2 2.2.15 hepatoblastoma cells were seeded in cell culture recipients
as described before (12). After seeding, culture medium, containing the drugs, was changed at days 3, 6 and 9. At
day 12 culture medium was harvested and clarified by centrifugation for determination of HBV DNA. The culture
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TABLE 1
Inhibitory Effect of 3TC, Cf 1109, and ddC on HIV Replication in Different CEM Cell Lines
EC50 (mM)a
CEM/0 CEM/TK0 CEM/dCK0
Compound HIV-1(IIIB) HIV-2(ROD) HIV-1/184 Val HIV-2(ROD) HIV-1(IIIB)
Cf 1109 2.5 3.0 250 5.5 65
3TC 0.01 0.02 250 0.07 30
ddC 0.04 0.01 0.04 0.03 20
So324 0.13 0.10 0.09 0.08b 0.12
d4T 0.35 0.30 0.22 33b 0.17
a 50% Effective concentration, or compound concentration required to inhibit HIV-induced cytopathicity by 50%.
b Data taken from ref. 13.
supernatants were prepared for dot blot analysis according to Korba and Milman (13) and applied to Hybond N/
membrane in the Convertible Filtration on Manifold.
Selection of HIV-1(IIIB) mutant strains resistant to 3TC and Cf 1109 administered as single drugs at fixed concentra-
tions. HIV-1(IIIB) was subjected to seven to eight passages in 5-ml CEM cell cultures (4 1 105 cells per ml) in the
presence of 2 mM 3TC or 10 mM Cf 1109 in 25-cm2 culture flasks (Falcon, Becton Dickinson) to produce mutant
HIV-1 strains. The multiplicity of the initial infection was at least 1000 times the 50% cell culture infective dose
(IC50). Passages were performed every 3-4 days by adding 0.5-1.0 ml of the infected culture supernatants to 4 to 4.5
ml of a suspension containing 4 1 105 uninfected CEM cells per ml. Syncytium formation was used as a parameter
of virus breakthrough in the cell cultures. After the 7th or 8th passage, the test compound concentrations were gradually
increased to 100 mM for Cf 1109 and 50 mM for 3TC as indicated in the footnote to Table 2.
Determination of the amino acid sequence of the RT of drug-resistant virus strains. The procedure of CEM cell
infection with mutant HIV-1 strains, preparation of the samples for PCR assays, amplification of the proviral DNA,
and sequencing of the 727 bp fragment covering amino acid residues 50-270 have been reported earlier (11,14). The
first set of primers (5*-GTAGAATTCTGTTGACTCAGATTGG-3* and 5*-TTCTGCCAGTTCTAGCTCTGCTTCT-
3*) gave a 900-bp product of the proviral RT gene. The second set of primers (5*-CCTGAAAATCCATACAATACT-
CCAGTATTTG-3* and 5*-AGTGCTTTGGTTCCTCTAAGGAGTTTAC-3*) gave the 727-bp RT fragment covering
amino acids 50-270. The PCR products were purified from 0.1% low-melting agarose gel by Magic PCR Preps
(Promega) or on a microspin column, and directly sequenced with an AutoRead T-7 Sequencing kit (Pharmacia).
Sequence analysis was then performed on an ALF DNA sequencer (Pharmacia).
RESULTS
Antiviral activity of Cf 1109, 3TC, and ddI against HIV-1 in different CEM cell lines. The
test compounds were evaluated on their antiviral efficiency against HIV in wild-type CEM/0
and the mutant thymidine kinase (TK)-deficient CEM/TK0 and 2*-deoxycytidine kinase (dCK)-
deficient CEM/dCK0 cell cultures (Table 1). 3TC and ddCyd proved 60- to 300-fold more
inhibitory against HIV-1 and HIV-2 replication in wild-type CEM/0 cell cultures than the
lipophylic 3TC-MP prodrug Cf 1109. All three cytosine derivatives kept full inhibitory potential
against HISV-2-infected TK-deficient CEM cells, but not against dCK-deficient CEM cells.
Interestingly, both ddC and 3TC showed a decreased antiviral potency by more than 3 orders
of magnitude whereas Cf 1109 lost its inhibitory potential only by 20-fold (Table 1). When
evaluated against 184-Val RT-mutated HIV-1, Cf 1109 had a  100-fold, and 3TC a 5,000-
fold decreased inhibitory effect.
Antiviral activity of 3TC and CF 1109 against extracellular release of HBV from HBV-
transfected Hep G2 2.2.15 cell cultures. The inhibitory effect of 3TC and Cf 1109 on the
extracellular release of HBV in supernatants of Hep G2 2.2.15 cell cultures has also been
evaluated (Fig. 2). Comparable results were obtained for the two drugs with an estimated 50%
effective concentration of 0.02 mM, as previously described for 3TC (14).
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FIG. 2. Evaluation of HBV DNA by dot blot hybridization, from cell culture supernatants of Hep G2 2.2.15 after
12 days of incubation in the presence of various drug concentrations. The cell cultures were exposed to 3TC or Cf
1109 at 0 (upper horizontal row), 0.01, 0.1, 1.0 and 10 mM (lowest horizontal row). The experiment was performed
in quadruplicate (vertical lanes).
Breakthrough of mutant HIV-1(IIIB) strains in the presence of 3TC and Cf 1109. The ability
of 3TC and Cf 1109 to suppress mutant virus breakthrough was then evaluated in wild-type
CEM cell cultures (Table 2). HIV-1-infected CEM cell cultures were treated with Cf 1109
and 3TC at 10 mM and 2 mM, respectively, that is at a 5- and 50-fold higher concentration
than their EC50 . Initial (microscopic) signs of virus breakthrough occurred at day 10 (for Cf
1109) and day 18 for 3TC. Full cytopathocity was reached under continued drug exposure at
days 21 and 24 for Cf 1109 and 3TC, respectively (Table 2). Gradual increases of drug
concentrations to 100 mM for Cf 1109 or 50 mM for 3TC did not markedly affected virus
replication in the cell cultures. Stocks of the mutant virus strains were prepared at day 45 post
infection.
Molecular characterisation of the mutant HIV-1 strains that emerged in the presence of Cf
1109 and 3TC. The amino acid substitutions in the RT of the virus strains that emerged in
the presence of Cf 1109 and 3TC were determined. The virus strain that emerged in the
continued presence of 3TC contained a 184 Met r Ile amino acid change in its RT (codon
ATG r ATA). The virus that emerged in the presence of Cf 1109 consisted of a mixture of
TABLE 2
Suppression of HIV-1-Induced Cytopathicity in CEM Cell Cultures (% of Control)
Days post infection
Concentration
Compound (mM) 3 7 10 14 18 21 24 27 31 35 38 42 45
Cf 1109 10 0 0 3 6.5 50 100 100a 100 100 100 100 100 100c
3TC 2 0 0 0 0 25 37 100 100b 100b 87 100 100 100c
a Initial Cf 1109 concentration was increased from 10 to 20 mM on day 24, from 20 to 50 mM on day 27, and from
50 to 100 mM on day 31 post infection and further subcultured in the presence of the test compound.
b Initial 3TC concentration was increased from 2 to 8 mM on day 27 and from 8 to 40 mM on day 31 post infection
and further subcultured in the presence of the test compound.
c Virus stocks were prepared on day 45 post infection.
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TABLE 3
Inhibitory Effect of NRTIs and NNRTIs on Mutant HIV-1 Replication in CEM Cell Cultures
EC50 (mg/ml)a
Mutant HIV-1(IIIB) strains containing the following amino acid changes in their RT
Compound IIIB (wild-type) 184-Ile (HIV-1/3TC) 184-Val/Ile (HIV-1/Cf 1109)
3TCb 0.05 3.6 30
Cf 1109b 1.1 60 250
ddCb 0.02 0.04 0.05
ddIb 2.3 5.1 6.5
AZTb 0.008 0.007 0.004
PMEAb 7.0 10 6.5
Nevirapine 0.022 0.021 0.010
BHAP U90,152 0.007 0.006 0.004
TIBO R82,913 0.023 0.020 0.011
a-APA 0.005 0.015 0.004
HBY 097 0.0007 0.025 0.041
TSAO-m 3T 0.018 0.025 0.041
UC-10 0.013 0.009 0.008
UC-781 0.001 0.002 0.001
UC-82 0.002 0.007 0.002
a 50% Effective concentration, or compound concentration required to inhibit HIV-1-induced giant cell formation
in CEM cell cultures by 50%.
b Data expressed in mM.
virus strains that contained a 184 Met r Val (codon ATG r GTG) or 184 Met r Ile (codon
ATG r ATA) in their RTs.
Sensitivity/resistance spectrum of the mutant virus strains that emerged in the presence of
3TC and Cf 1109. The sensitivity/resistance spectrum of the mutant viruses that broke through
in the presence of 3TC and Cf 1109 in the HIV-1-infected CEM cell cultures was determined
for a variety of nucleoside RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs)
and compared with the parental wild-type virus (Table 3). Among the NRTIs, only 3TC (and
Cf 1109) showed a markedly decreased antiviral activity against both HIV-1/184 Ile and HIV-
1/184 Val/Ile viruses. The activity of 3TC was almost 100-fold (for HIV-1/184 Ile) to 1,000-
fold (for HIV-1/184 Val) decreased. Cf 1109 completely lost its inhibitory potential against
both mutant viruses at 250 mg/ml. In contrast, DDC nor ddI, AZT and PMEA lost their antiviral
activity against the mutant virus strains. Also, prototype members of a variety of 7 different
NNRTI classes virtually kept full inhibitory potential against mutant HIV-1/184 Ile and HIV-
1/184 Val/Ile when compared with wild-type virus (Table 3).
DISCUSSION
Recently, we developed a successful approach to efficiently deliver the 5*-monophosphate
of d4T into intact CEM cells (15,16). The arylphosphoramidate derivative of d4T (So324)
proved at least as effective if not more efficient in inhibiting HIV replication in cell culture
than the parental nucleoside d4T. We could also show that So324, in sharp contrast with d4T,
kept its full antiviral efficacy in thymidine kinase-deficient CEM cell cultures. The latter
observation, together with metabolism experiments in CEM/0 and CEM/TK0 cell cultures,
using radiolabeled So324 and d4T, strongly pointed to the ability of So324 to deliver directly
d4T-MP in the intact cells. To overcome the dependence on phosphorylation of 3TC by
cytosolic dCyd kinase, an analogous approach was followed.
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Surprisingly, the 3TC prodrug Cf 1109 proved  250-fold less active against HIV than
3TC. This is in sharp contrast with the analogous prodrugs of AZT (designated So221) (17)
and d4T (designated So324) (15,16) that showed virtually comparable, if not superior, antiviral
activity than the parental AZT and d4T nucleosides. This observation can be explained by a
much poorer uptake of the 3TC prodrug compared to the d4T and AZT prodrugs, and/or to a
markedly lower efficiency of the intracellular release of the nucleoside or nucleotide. Although
we do not have experimental proof, we do believe that the first possibility is unlikely since
these highly lipophilic compounds are thought to enter the cells by passive diffusion which
is supposedly rather independent on the nature of the nucleoside sugar part. Therefore, a
relatively low efficiency of intracellular release of 3TC and 3TC-MP from the prodrug Cf
1109 is more likely to explain the lower antiviral activity of Cf 1109 than 3TC in CEM cells.
3TC and Cf 1109 are virtually equally effective against HBV in Hep G2 2.2.15 cells. Obviously,
the enzymes that may release 3TC and/or 3TC-MP from Cf 1109 clearly differ in the human
hepatoblastoma Hep G2 2.2.15 and lymphocyte CEM cells. It is also noteworthy that the d4T-
MP prodrug So324, that showed a higher anti-HIV efficacy than d4T in cell culture, was not
endowed with a marked anti-HBV activity (EC50 for d4T and So324:  10 mM) in the Hep G2
2.2.14 hepatoblastoma cell cultures. Thus, whereas So324 proved superior to Cf 1109 against HIV,
the d4T-MP prodrug was inferior to the 3TC-MP prodrug against HBV.
In contrast with the d4T-MP prodrug So324, Cf 1109 markedly lost (20-fold) antiviral
potency in HIV-infected CEM cell cultures that lacked the enzyme phosphorylating 3TC (i.e.
CEM/dCK0). However, our observation that the parental nucleoside 3TC lost more than 1,500-
fold its antiviral potential under identical experimental conditions points to some delivery of
3TC-MP within the intact cells, albeit at relatively low efficiency (estimated to be  5%).
This relatively low delivery of 3TC-MP from Cf 1109 in the intact CEM cells contrasts with
the markedly more efficient delivery of d4T-MP from So324 (15,16) and may likely be due
to different substrate specificities of esterases and/or other enzyme activities that may determine
the eventual delivery of 3TC and/or 3TC-MP from Cf 1109. The pathways followed by So324
and Cf 1109 to deliver d4T-MP and 3TC-MP, respectively, are currently under investigation.
However, modifications in the aryl part and/or the amino acid part of the 3TC prodrug may
be required to improve the stability and/or depot-function of Cf 1109 for 3TC and 3TC-MP.
The fact that both Cf 1109 and 3TC virtually give an identical resistance spectrum (both
in selection of mutant virus strains and the sensitivity/resistance profile) is strongly suggestive
for a common mechanism of HIV (and HBV) inhibition by these compounds: i.e. conversion
of the compounds to 3TC-TP, followed by inhibition of the HIV RT and HBV DNA polymerase
by 3TC-TP.
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